Juniper Pharmaceuticals

The Company has a successful history in developing pharmaceutical products, including Crinone® 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world.

We are currently developing several product candidates using our segmented intravaginal ring (IVR) technology. The most advanced of these is JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women.

We are leveraging the in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services to advance an internal product pipeline, while also providing valuable intellectual property-related consultative services to our pharmaceutical industry customers.

Juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to advance a proprietary pipeline for long term value creation.

Type
Public
HQ
Boston, US
Founded
1986
Size (employees)
139 (est)+33%
Juniper Pharmaceuticals was founded in 1986 and is headquartered in Boston, US

Juniper Pharmaceuticals Office Locations

Juniper Pharmaceuticals has an office in Boston
Boston, US (HQ)
33 Arch St

Juniper Pharmaceuticals Data and Metrics

Juniper Pharmaceuticals Financial Metrics

Juniper Pharmaceuticals's revenue was reported to be $54.6 m in FY, 2016 which is a 45% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

54.6 m

Revenue growth (FY, 2015 - FY, 2016), %

45%

Gross profit (FY, 2016)

30.3 m

Gross profit margin (FY, 2016), %

55%

Net income (FY, 2016)

6 m

EBIT (FY, 2016)

5.3 m

Market capitalization (21-Jun-2017)

59.1 m

Closing share price (21-Jun-2017)

5.4

Cash (31-Dec-2016)

21 m

EV

38.5 m
Juniper Pharmaceuticals's current market capitalization is $59.1 m.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

29.2 m32.5 m37.6 m54.6 m

Revenue growth, %

11%16%45%

Cost of goods sold

13.3 m17.7 m21.4 m24.3 m

Gross profit

16 m14.8 m16.1 m30.3 m

Gross profit Margin, %

55%46%43%55%

Operating expense total

10.1 m11 m18.7 m25 m

EBIT

5.9 m3.8 m(2.5 m)5.3 m

EBIT margin, %

20%12%(7%)10%

Interest expense

(97 k)

Interest income

(97 k)

Pre tax profit

6.7 m4.4 m(2.1 m)6 m

Income tax expense

22.6 k988 k5 k91 k

Net Income

6.7 m3.4 m(2.1 m)6 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.7 m16.8 m13.9 m21 m

Accounts Receivable

7.2 m5.3 m

Inventories

2.6 m3.2 m3.6 m5.6 m

Current Assets

32.2 m26.4 m26.7 m34.7 m

PP&E

13.2 m13 m12.9 m13.4 m

Goodwill

11.2 m10.5 m10 m8.3 m

Total Assets

60.1 m52.2 m51.4 m57.6 m

Accounts Payable

2.8 m2.9 m2 m3.9 m

Total Debt

500.3 k486 k476 k408 k

Current Liabilities

6.3 m5.9 m7.7 m15 m

Additional Paid-in Capital

287 m287.7 m289.5 m290.6 m

Retained Earnings

(241.7 m)(238.3 m)(240.4 m)(237.4 m)

Total Equity

46.9 m40.9 m39.4 m39.8 m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.3 x1.3 x1.3 x1.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

6.7 m3.4 m(2.1 m)6 m

Depreciation and Amortization

919.1 k2 m1.9 m1.9 m

Accounts Receivable

(2.3 m)1.7 m(2.5 m)192 k

Inventories

46.5 k(619 k)(424 k)(2 m)

Accounts Payable

314.8 k91 k(925 k)1.6 m

Cash From Operating Activities

7.1 m6.9 m(891 k)11.2 m

Purchases of PP&E

(522.4 k)(2 m)(1.7 m)(3.6 m)

Cash From Investing Activities

315.1 k(2 m)(1.7 m)(3.6 m)

Short-term Borrowings

(72.3 k)(245 k)(238 k)(226 k)

Dividends Paid

(27.5 k)(28 k)(28 k)(28 k)

Cash From Financing Activities

(89.1 k)(8.7 m)(206 k)(254 k)

Interest Paid

24.9 k120 k101 k85 k

Income Taxes Paid

3 k3 k2 k2 k
Numbers are in $, USDY, 2016

EV/EBIT

7.3 x

EV/CFO

3.4 x

Revenue/Employee

519.7 k

Financial Leverage

1.4 x

Juniper Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

4

Juniper Pharmaceuticals Market Value History

Juniper Pharmaceuticals Job Categories

Juniper Pharmaceuticals Company Life and Culture

You may also be interested in